首页 > 最新文献

The Journal of Headache and Pain最新文献

英文 中文
The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders 世界卫生组织部门间癫痫和其他神经系统疾病全球行动计划与头痛革命:从头痛负担到头痛疾病全球行动计划
Pub Date : 2024-01-04 DOI: 10.1186/s10194-023-01700-3
Matilde Leonardi, Paolo Martelletti, Rami Burstein, Arianna Fornari, Licia Grazzi, Alla Guekht, Richard B. Lipton, Dimos Dimitrios Mitsikostas, Jes Olesen, Mayowa Ojo Owolabi, Elena Ruiz De la Torre, Simona Sacco, Timothy J. Steiner, Nirmal Surya, Takao Takeshima, Cristina Tassorelli, Shuu-Jiun Wang, Tissa Wijeratne, Shengyuan Yu, Alberto Raggi
The World Health Organization (WHO) Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders was developed by WHO to address the worldwide challenges and gaps in provision of care and services for people with epilepsy and other neurological disorders and to ensure a comprehensive, coordinated response across sectors to the burden of neurologic diseases and to promote brain health across life-course. Headache disorders constitute the second most burdensome of all neurological diseases after stroke, but the first if young and midlife adults are taken into account. Despite the availability of a range of treatments, disability associated with headache disorders, and with migraine, remains very high. In addition, there are inequalities between high-income and low and middle income countries in access to medical care. In line with several brain health initiatives following the WHOiGAP resolution, herein we tailor the main pillars of the action plan to headache disorders: (1) raising policy prioritization and strengthen governance; (2) providing effective, timely and responsive diagnosis, treatment and care; (3) implementing strategies for promotion and prevention; (4) fostering research and innovation and strengthen information systems. Specific targets for future policy actions are proposed. The Global Action Plan triggered a revolution in neurology, not only by increasing public awareness of brain disorders and brain health but also by boosting the number of neurologists in training, raising research funding and making neurology a public health priority for policy makers. Reducing the burden of headache disorders will not only improve the quality of life and wellbeing of people with headache but also reduce the burden of neurological disorders increasing global brain health and, thus, global population health.
世界卫生组织(WHO)制定了《癫痫和其他神经系统疾病跨部门全球行动计划》,以应对全球范围内为癫痫和其他神经系统疾病患者提供护理和服务方面的挑战和差距,确保各部门全面、协调地应对神经系统疾病带来的负担,促进整个生命过程中的脑健康。在所有神经系统疾病中,头痛是仅次于中风的第二大负担,但如果考虑到中青年,头痛则是第一大负担。尽管有一系列治疗方法,但与头痛症和偏头痛相关的残疾率仍然很高。此外,高收入国家与中低收入国家在获得医疗服务方面也存在不平等。根据世界卫生组织《全球行动计划》(WHOiGAP)决议提出的若干脑健康倡议,我们在此为头痛症量身定制了行动计划的主要支柱:(1) 提高政策的优先性并加强治理;(2) 提供有效、及时和反应迅速的诊断、治疗和护理;(3) 实施促进和预防战略;(4) 促进研究和创新并加强信息系统。提出了未来政策行动的具体目标。全球行动计划》引发了神经病学领域的一场革命,不仅提高了公众对脑部疾病和脑部健康的认识,还增加了接受培训的神经病学专家的人数,提高了研究经费,并使神经病学成为政策制定者优先考虑的公共卫生问题。减轻头痛疾病的负担不仅能改善头痛患者的生活质量和福祉,还能减轻神经系统疾病的负担,提高全球脑健康水平,进而提高全球人口健康水平。
{"title":"The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders","authors":"Matilde Leonardi, Paolo Martelletti, Rami Burstein, Arianna Fornari, Licia Grazzi, Alla Guekht, Richard B. Lipton, Dimos Dimitrios Mitsikostas, Jes Olesen, Mayowa Ojo Owolabi, Elena Ruiz De la Torre, Simona Sacco, Timothy J. Steiner, Nirmal Surya, Takao Takeshima, Cristina Tassorelli, Shuu-Jiun Wang, Tissa Wijeratne, Shengyuan Yu, Alberto Raggi","doi":"10.1186/s10194-023-01700-3","DOIUrl":"https://doi.org/10.1186/s10194-023-01700-3","url":null,"abstract":"The World Health Organization (WHO) Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders was developed by WHO to address the worldwide challenges and gaps in provision of care and services for people with epilepsy and other neurological disorders and to ensure a comprehensive, coordinated response across sectors to the burden of neurologic diseases and to promote brain health across life-course. Headache disorders constitute the second most burdensome of all neurological diseases after stroke, but the first if young and midlife adults are taken into account. Despite the availability of a range of treatments, disability associated with headache disorders, and with migraine, remains very high. In addition, there are inequalities between high-income and low and middle income countries in access to medical care. In line with several brain health initiatives following the WHOiGAP resolution, herein we tailor the main pillars of the action plan to headache disorders: (1) raising policy prioritization and strengthen governance; (2) providing effective, timely and responsive diagnosis, treatment and care; (3) implementing strategies for promotion and prevention; (4) fostering research and innovation and strengthen information systems. Specific targets for future policy actions are proposed. The Global Action Plan triggered a revolution in neurology, not only by increasing public awareness of brain disorders and brain health but also by boosting the number of neurologists in training, raising research funding and making neurology a public health priority for policy makers. Reducing the burden of headache disorders will not only improve the quality of life and wellbeing of people with headache but also reduce the burden of neurological disorders increasing global brain health and, thus, global population health.","PeriodicalId":501630,"journal":{"name":"The Journal of Headache and Pain","volume":"184 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139095770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Mechanisms of initiation of cortical spreading depression 更正:皮层扩散抑制的启动机制
Pub Date : 2023-12-20 DOI: 10.1186/s10194-023-01702-1
Marina Vitale, Angelita Tottene, Maral Zarin Zadeh, K. C. Brennan, Daniela Pietrobon

Correction: J Headache Pain 24, 105 (2023)

https://doi.org/10.1186/s10194-023-01643-9

In the original version of this article [1], on page 2, in the second paragraph of the right-hand column, the text reads: “ On the other hand, mutant mice carrying mutations, which cause partial loss-of-function of CaV2.1 channels and reduced K+-evoked glutamate rise, showed a lower CSD stimulation threshold” but it should have read: “ On the other hand, mutant mice carrying mutations, which cause partial loss-of-function of CaV2.1 channels and reduced K + -evoked glutamate rise, showed an increased CSD stimulation threshold”.

The original article has been corrected.

  1. Vitale M, Tottene A, Zarin Zadeh M et al (2023) Mechanisms of initiation of cortical spreading depression. J Headache Pain 24:105. https://doi.org/10.1186/s10194-023-01643-9

    Article CAS PubMed PubMed Central Google Scholar

Download references

Author notes
  1. Marina Vitale and Angelita Tottene contributed equally.

Authors and Affiliations

  1. Department of Biomedical Sciences, University of Padova, 35131, Padua, Italy

    Marina Vitale, Angelita Tottene, Maral Zarin Zadeh & Daniela Pietrobon

  2. Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT, 84108, USA

    K. C. Brennan

  3. Padova Neuroscience Center (PNC), University of Padova, 35131, Padua, Italy

    Daniela Pietrobon

Authors
  1. Marina VitaleView author publications

    You can also search for this author in PubMed Google Scholar

  2. Angelita TotteneView author publications

    You can also search for this author in PubMed Google Scholar

  3. Maral Zarin ZadehView author publications

    You can also search for this author in PubMed Google Scholar

  4. K. C. BrennanView author publications

    You can also search for this author in PubMed Google Scholar

  5. Daniela PietrobonView author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniela Pietrobon.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons

更正:J Headache Pain 24, 105 (2023)https://doi.org/10.1186/s10194-023-01643-9In 本文[1]的原始版本第 2 页右栏第二段中的内容如下:另一方面,携带导致 CaV2.1 通道部分功能缺失和 K+诱发谷氨酸升高的突变基因的突变小鼠显示出较低的 CSD 刺激阈值",但应改为 "另一方面,携带导致 CaV2.1 通道部分功能缺失和 K+诱发谷氨酸升高的突变基因的突变小鼠显示出较低的 CSD 刺激阈值":"另一方面,携带导致 CaV2.1 通道部分功能缺失和 K + 诱发的谷氨酸升高的突变小鼠显示出更高的 CSD 刺激阈值"。原文已更正。Vitale M、Tottene A、Zarin Zadeh M 等人(2023 年):皮层扩散抑制的启动机制。J Headache Pain 24:105. https://doi.org/10.1186/s10194-023-01643-9Article CAS PubMed PubMed Central Google Scholar Download referencesAuthor notesMarina Vitale and Angelita Tottene contributions equally.作者及工作单位帕多瓦大学生物医学科学系,35131,帕多瓦,意大利Marina Vitale, Angelita Tottene, Maral Zarin Zadeh & Daniela Pietrobon犹他大学医学院神经病学系,盐湖城,UT,84108,USAK.C. BrennanPadova Neuroscience Center (PNC), University of Padova, 35131, Padua, ItalyDaniela PietrobonAuthorsMarina VitaleView Author publications您也可以在PubMed Google ScholarAngelita TotteneView Author publications您也可以在PubMed Google ScholarMaral Zarin ZadehView Author publications您也可以在PubMed Google ScholarK.C. BrennanView author publications您也可以在PubMed Google Scholar中搜索该作者Daniela PietrobonView author publications您也可以在PubMed Google Scholar中搜索该作者Corresponding authorCorrespondence to Daniela Pietrobon.Open Access本文采用知识共享署名 4.0 国际许可协议进行许可。0 国际许可协议,该协议允许以任何媒介或格式使用、共享、改编、分发和复制本文,但需注明原作者和出处,提供知识共享许可协议的链接,并说明是否进行了修改。本文中的图片或其他第三方材料均包含在文章的知识共享许可协议中,除非在材料的署名栏中另有说明。如果材料未包含在文章的知识共享许可协议中,且您打算使用的材料不符合法律规定或超出许可使用范围,您需要直接从版权所有者处获得许可。要查看该许可的副本,请访问 http://creativecommons.org/licenses/by/4.0/。除非在数据的信用行中另有说明,否则知识共享公共领域专用免责声明 (http://creativecommons.org/publicdomain/zero/1.0/) 适用于本文提供的数据。转载与许可引用本文Vitale, M., Tottene, A., Zadeh, M.Z. et al. Correction:皮质扩散抑制的启动机制。J Headache Pain 24, 171 (2023). https://doi.org/10.1186/s10194-023-01702-1Download citationPublished: 20 December 2023DOI: https://doi.org/10.1186/s10194-023-01702-1Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative
{"title":"Correction: Mechanisms of initiation of cortical spreading depression","authors":"Marina Vitale, Angelita Tottene, Maral Zarin Zadeh, K. C. Brennan, Daniela Pietrobon","doi":"10.1186/s10194-023-01702-1","DOIUrl":"https://doi.org/10.1186/s10194-023-01702-1","url":null,"abstract":"<p>\u0000<b>Correction: J Headache Pain 24, 105 (2023)</b>\u0000</p><p>\u0000<b>https://doi.org/10.1186/s10194-023-01643-9</b>\u0000</p><p>In the original version of this article [1], on page 2, in the second paragraph of the right-hand column, the text reads: “ On the other hand, mutant mice carrying mutations, which cause partial loss-of-function of CaV2.1 channels and reduced K<sup>+</sup>-evoked glutamate rise, showed a lower CSD stimulation threshold” but it should have read: “ On the other hand, mutant mice carrying mutations, which cause partial loss-of-function of CaV2.1 channels and reduced K + -evoked glutamate rise, showed <b>an increased</b> CSD stimulation threshold”.</p><p>The original article has been corrected.</p><ol data-track-component=\"outbound reference\"><li data-counter=\"1.\"><p>Vitale M, Tottene A, Zarin Zadeh M et al (2023) Mechanisms of initiation of cortical spreading depression. J Headache Pain 24:105. https://doi.org/10.1186/s10194-023-01643-9</p><p>Article CAS PubMed PubMed Central Google Scholar </p></li></ol><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><span>Author notes</span><ol><li><p>Marina Vitale and Angelita Tottene contributed equally.</p></li></ol><h3>Authors and Affiliations</h3><ol><li><p>Department of Biomedical Sciences, University of Padova, 35131, Padua, Italy</p><p>Marina Vitale, Angelita Tottene, Maral Zarin Zadeh &amp; Daniela Pietrobon</p></li><li><p>Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT, 84108, USA</p><p>K. C. Brennan</p></li><li><p>Padova Neuroscience Center (PNC), University of Padova, 35131, Padua, Italy</p><p>Daniela Pietrobon</p></li></ol><span>Authors</span><ol><li><span>Marina Vitale</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Angelita Tottene</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Maral Zarin Zadeh</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>K. C. Brennan</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Daniela Pietrobon</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li></ol><h3>Corresponding author</h3><p>Correspondence to Daniela Pietrobon.</p><p><b>Open Access</b> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons ","PeriodicalId":501630,"journal":{"name":"The Journal of Headache and Pain","volume":"483 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138818351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between impaired dynamic cerebral autoregulation and BBB disruption in reversible cerebral vasoconstriction syndrome 可逆性脑血管收缩综合征的动态脑自动调节功能受损与 BBB 破坏之间的关系
Pub Date : 2023-12-19 DOI: 10.1186/s10194-023-01694-y
Yu-Hsiang Ling, Nai-Fang Chi, Li-Ling Hope Pan, Yen-Feng Wang, Chia-Hung Wu, Jiing-Feng Lirng, Jong-Ling Fuh, Shuu-Jiun Wang, Shih-Pin Chen
Half of the sufferers of reversible cerebral vasoconstriction syndrome (RCVS) exhibit imaging-proven blood-brain barrier disruption. The pathogenesis of blood-brain barrier disruption in RCVS remains unclear and mechanism-specific intervention is lacking. We speculated that cerebrovascular dysregulation might be associated with blood-brain barrier disruption in RCVS. Hence, we aimed to evaluate whether the dynamic cerebral autoregulation is altered in patients with RCVS and could be associated with blood-brain barrier disruption. A cross-sectional study was conducted from 2019 to 2021 at headache clinics of a national tertiary medical center. Dynamic cerebral autoregulation was evaluated in all participants. The capacity of the dynamic cerebral autoregulation to damp the systemic hemodynamic changes, i.e., phase shift and gain between the cerebral blood flow and blood pressure waveforms in the very-low- and low-frequency bands were calculated by transfer function analysis. The mean flow correlation index was also calculated. Patients with RCVS received 3-dimensional isotropic contrast-enhanced T2 fluid-attenuated inversion recovery imaging to visualize blood-brain barrier disruption. Forty-five patients with RCVS (41.9 ± 9.8 years old, 29 females) and 45 matched healthy controls (41.4 ± 12.5 years old, 29 females) completed the study. Nineteen of the patients had blood-brain barrier disruption. Compared to healthy controls, patients with RCVS had poorer dynamic cerebral autoregulation, indicated by higher gain in very-low-frequency band (left: 1.6 ± 0.7, p = 0.001; right: 1.5 ± 0.7, p = 0.003; healthy controls: 1.1 ± 0.4) and higher mean flow correlation index (left: 0.39 ± 0.20, p = 0.040; right: 0.40 ± 0.18, p = 0.017; healthy controls: 0.31 ± 0.17). Moreover, patients with RCVS with blood-brain barrier disruption had worse dynamic cerebral autoregulation, as compared to those without blood-brain barrier disruption, by having less phase shift in very-low- and low-frequency bands, and higher mean flow correlation index. Dysfunctional dynamic cerebral autoregulation was observed in patients with RCVS, particularly in those with blood-brain barrier disruption. These findings suggest that impaired cerebral autoregulation plays a pivotal role in RCVS pathophysiology and may be relevant to complications associated with blood-brain barrier disruption by impaired capacity of maintaining stable cerebral blood flow under fluctuating blood pressure.
半数可逆性脑血管收缩综合征(RCVS)患者表现出影像学证实的血脑屏障破坏。可逆性脑血管收缩综合征(RCVS)中血脑屏障破坏的发病机制尚不清楚,也缺乏针对具体机制的干预措施。我们推测,脑血管失调可能与 RCVS 中的血脑屏障破坏有关。因此,我们旨在评估 RCVS 患者的动态脑自动调节是否发生改变,以及是否与血脑屏障破坏有关。一项横断面研究于 2019 年至 2021 年在一家国家三级医疗中心的头痛诊所进行。对所有参与者的动态脑自动调节功能进行了评估。通过传递函数分析,计算了动态脑自动调节抑制全身血液动力学变化的能力,即脑血流和血压波形在极低频和低频波段的相移和增益。同时还计算了平均血流相关指数。RCVS 患者接受了三维各向同性对比增强 T2 流体衰减反转恢复成像,以观察血脑屏障的破坏情况。45 名 RCVS 患者(41.9 ± 9.8 岁,29 名女性)和 45 名匹配的健康对照者(41.4 ± 12.5 岁,29 名女性)完成了研究。其中 19 名患者存在血脑屏障破坏。与健康对照组相比,RCVS 患者的动态脑自动调节功能较差,表现为极低频段增益较高(左侧:1.6 ± 0.7,p = 0.001;右侧:1.5 ± 0.7,p = 0.003;健康对照组:1.1 ± 0.4):1.1 ± 0.4)和更高的平均血流相关指数(左:0.39 ± 0.20,p = 0.040;右:0.40 ± 0.18,p = 0.017;健康对照组:0.31 ± 0.17):0.31 ± 0.17).此外,与无血脑屏障破坏的患者相比,伴有血脑屏障破坏的 RCVS 患者的动态脑自动调节功能较差,表现为极低频和低频波段的相移较少,平均血流相关指数较高。在 RCVS 患者中,尤其是在血脑屏障受损的患者中,观察到大脑动态自调节功能失调。这些研究结果表明,大脑自动调节功能受损在 RCVS 病理生理学中起着关键作用,并可能与血脑屏障破坏引起的并发症有关,因为它削弱了在血压波动的情况下维持稳定脑血流的能力。
{"title":"Association between impaired dynamic cerebral autoregulation and BBB disruption in reversible cerebral vasoconstriction syndrome","authors":"Yu-Hsiang Ling, Nai-Fang Chi, Li-Ling Hope Pan, Yen-Feng Wang, Chia-Hung Wu, Jiing-Feng Lirng, Jong-Ling Fuh, Shuu-Jiun Wang, Shih-Pin Chen","doi":"10.1186/s10194-023-01694-y","DOIUrl":"https://doi.org/10.1186/s10194-023-01694-y","url":null,"abstract":"Half of the sufferers of reversible cerebral vasoconstriction syndrome (RCVS) exhibit imaging-proven blood-brain barrier disruption. The pathogenesis of blood-brain barrier disruption in RCVS remains unclear and mechanism-specific intervention is lacking. We speculated that cerebrovascular dysregulation might be associated with blood-brain barrier disruption in RCVS. Hence, we aimed to evaluate whether the dynamic cerebral autoregulation is altered in patients with RCVS and could be associated with blood-brain barrier disruption. A cross-sectional study was conducted from 2019 to 2021 at headache clinics of a national tertiary medical center. Dynamic cerebral autoregulation was evaluated in all participants. The capacity of the dynamic cerebral autoregulation to damp the systemic hemodynamic changes, i.e., phase shift and gain between the cerebral blood flow and blood pressure waveforms in the very-low- and low-frequency bands were calculated by transfer function analysis. The mean flow correlation index was also calculated. Patients with RCVS received 3-dimensional isotropic contrast-enhanced T2 fluid-attenuated inversion recovery imaging to visualize blood-brain barrier disruption. Forty-five patients with RCVS (41.9 ± 9.8 years old, 29 females) and 45 matched healthy controls (41.4 ± 12.5 years old, 29 females) completed the study. Nineteen of the patients had blood-brain barrier disruption. Compared to healthy controls, patients with RCVS had poorer dynamic cerebral autoregulation, indicated by higher gain in very-low-frequency band (left: 1.6 ± 0.7, p = 0.001; right: 1.5 ± 0.7, p = 0.003; healthy controls: 1.1 ± 0.4) and higher mean flow correlation index (left: 0.39 ± 0.20, p = 0.040; right: 0.40 ± 0.18, p = 0.017; healthy controls: 0.31 ± 0.17). Moreover, patients with RCVS with blood-brain barrier disruption had worse dynamic cerebral autoregulation, as compared to those without blood-brain barrier disruption, by having less phase shift in very-low- and low-frequency bands, and higher mean flow correlation index. Dysfunctional dynamic cerebral autoregulation was observed in patients with RCVS, particularly in those with blood-brain barrier disruption. These findings suggest that impaired cerebral autoregulation plays a pivotal role in RCVS pathophysiology and may be relevant to complications associated with blood-brain barrier disruption by impaired capacity of maintaining stable cerebral blood flow under fluctuating blood pressure. ","PeriodicalId":501630,"journal":{"name":"The Journal of Headache and Pain","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138745221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Machine learning approach for Migraine Aura Complexity Score prediction based on magnetic resonance imaging data 基于磁共振成像数据的偏头痛先兆复杂性评分预测机器学习方法
Pub Date : 2023-12-18 DOI: 10.1186/s10194-023-01704-z
Katarina Mitrović, Andrej M. Savić, Aleksandra Radojičić, Marko Daković, Igor Petrušić
Previous studies have developed the Migraine Aura Complexity Score (MACS) system. MACS shows great potential in studying the complexity of migraine with aura (MwA) pathophysiology especially when implemented in neuroimaging studies. The use of sophisticated machine learning (ML) algorithms, together with deep profiling of MwA, could bring new knowledge in this field. We aimed to test several ML algorithms to study the potential of structural cortical features for predicting the MACS and therefore gain a better insight into MwA pathophysiology. The data set used in this research consists of 340 MRI features collected from 40 MwA patients. Average MACS score was obtained for each subject. Feature selection for ML models was performed using several approaches, including a correlation test and a wrapper feature selection methodology. Regression was performed with the Support Vector Machine (SVM), Linear Regression, and Radial Basis Function network. SVM achieved a 0.89 coefficient of determination score with a wrapper feature selection. The results suggest a set of cortical features, located mostly in the parietal and temporal lobes, that show changes in MwA patients depending on aura complexity. The SVM algorithm demonstrated the best potential in average MACS prediction when using a wrapper feature selection methodology. The proposed method achieved promising results in determining MwA complexity, which can provide a basis for future MwA studies and the development of MwA diagnosis and treatment.
以往的研究已开发出偏头痛先兆复杂性评分(MACS)系统。MACS在研究先兆性偏头痛(MwA)病理生理学的复杂性方面显示出巨大的潜力,尤其是在神经影像学研究中应用时。使用复杂的机器学习(ML)算法,再加上对 MwA 的深入剖析,可为这一领域带来新的知识。我们的目的是测试几种 ML 算法,研究皮层结构特征预测 MACS 的潜力,从而更好地了解 MwA 的病理生理学。本研究使用的数据集包括从 40 名 MwA 患者身上收集的 340 个 MRI 特征。每个受试者都获得了 MACS 平均得分。使用多种方法为 ML 模型选择特征,包括相关性测试和包装特征选择方法。使用支持向量机 (SVM)、线性回归和径向基函数网络进行回归。使用包装特征选择法,SVM 的决定系数达到了 0.89。结果表明,一组主要位于顶叶和颞叶的皮层特征在 MwA 患者中会根据先兆复杂性而发生变化。在使用包装特征选择方法时,SVM 算法在平均 MACS 预测方面表现出最佳潜力。所提出的方法在确定 MwA 复杂性方面取得了可喜的成果,可为今后的 MwA 研究以及 MwA 诊断和治疗的发展提供依据。
{"title":"Machine learning approach for Migraine Aura Complexity Score prediction based on magnetic resonance imaging data","authors":"Katarina Mitrović, Andrej M. Savić, Aleksandra Radojičić, Marko Daković, Igor Petrušić","doi":"10.1186/s10194-023-01704-z","DOIUrl":"https://doi.org/10.1186/s10194-023-01704-z","url":null,"abstract":"Previous studies have developed the Migraine Aura Complexity Score (MACS) system. MACS shows great potential in studying the complexity of migraine with aura (MwA) pathophysiology especially when implemented in neuroimaging studies. The use of sophisticated machine learning (ML) algorithms, together with deep profiling of MwA, could bring new knowledge in this field. We aimed to test several ML algorithms to study the potential of structural cortical features for predicting the MACS and therefore gain a better insight into MwA pathophysiology. The data set used in this research consists of 340 MRI features collected from 40 MwA patients. Average MACS score was obtained for each subject. Feature selection for ML models was performed using several approaches, including a correlation test and a wrapper feature selection methodology. Regression was performed with the Support Vector Machine (SVM), Linear Regression, and Radial Basis Function network. SVM achieved a 0.89 coefficient of determination score with a wrapper feature selection. The results suggest a set of cortical features, located mostly in the parietal and temporal lobes, that show changes in MwA patients depending on aura complexity. The SVM algorithm demonstrated the best potential in average MACS prediction when using a wrapper feature selection methodology. The proposed method achieved promising results in determining MwA complexity, which can provide a basis for future MwA studies and the development of MwA diagnosis and treatment.","PeriodicalId":501630,"journal":{"name":"The Journal of Headache and Pain","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138716468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health equity, care access and quality in headache – part 2 令人头痛的医疗公平、医疗服务的获取和质量--第 2 部分
Pub Date : 2023-12-13 DOI: 10.1186/s10194-023-01699-7
Bianca Raffaelli, Eloísa Rubio-Beltrán, Soo-Jin Cho, Roberto De Icco, Alejandro Labastida-Ramirez, Dilara Onan, Raffaele Ornello, Ruth Ruscheweyh, Marta Waliszewska-Prosół, Roberta Messina, Francesca Puledda
Headache disorders are a global public health concern affecting diverse populations. This review examines headache service organizations in low-, middle-, and high-income countries. It addresses global challenges in pharmacological headache treatment, with a focus on safety, tolerability, reproductive and child health, and outlines disparities in accessing innovative treatments worldwide. Organized headache services are essential due to the wide prevalence and varying severity of headache disorders. The tiered headache service model is globally recognized, although its implementation varies based on financial and workforce considerations. Headache burden affects well-being, causing disability, economic challenges, and work limitations, irrespective of location or income. All nations still require improved diagnosis and treatment, and the majority of countries face obstacles including limited access, awareness, economic barriers, and inadequate health policies. Provided adequate internet availability, telemedicine could help improve health equity by expanding access to headache care, since it can offer patients access to services without lengthy waiting times or extensive travel and can provide healthcare unavailable in underserved areas due to staff shortages. Numerous health disparities restrict global access to many headache medications, especially impacting individuals historically excluded from randomized controlled trials, such as those with cardiovascular and cerebrovascular conditions, as well as pregnant women. Furthermore, despite advancements in researching migraine treatments for young patients, the options for treatment remain limited. Access to headache treatment relies on factors like medication availability, approval, financial coverage, and healthcare provider expertise. Inadequate public awareness leads to neglect by policymakers and undertreatment by patients and healthcare providers. Global access discrepancies are exacerbated by the introduction of novel disease-specific medications, particularly impacting Asian, African, and Latin American nations excluded from clinical trials. While North America and Europe experience broad availability of migraine treatments, the majority of countries worldwide lack access to these therapies. Healthcare disparities, treatment access, and medication availability are concerning issues in headache medicine. Variations in national healthcare systems impact headache management, and costly innovative drugs are widening these gaps. Healthcare practitioners and experts should acknowledge these challenges and work towards minimizing access barriers for equitable global headache care in the future.
头痛疾病是影响不同人群的全球性公共健康问题。本综述研究了低收入、中等收入和高收入国家的头痛服务机构。它探讨了头痛药物治疗所面临的全球性挑战,重点关注安全性、耐受性、生殖健康和儿童健康,并概述了世界各地在获得创新治疗方面存在的差异。由于头痛疾病发病率高且严重程度不同,有组织的头痛服务至关重要。分级头痛服务模式已得到全球认可,但其实施情况因财政和劳动力方面的考虑而有所不同。头痛负担影响着人们的福祉,导致残疾、经济困难和工作限制,与地点或收入无关。所有国家仍然需要改进诊断和治疗,而大多数国家都面临着各种障碍,包括获取途径有限、认识不足、经济障碍和卫生政策不完善。如果有足够的互联网可用性,远程医疗可以通过扩大头痛护理的可及性帮助改善健康公平,因为它可以为患者提供服务,而无需漫长的等待时间或长途跋涉,还可以为服务不足地区提供因人员短缺而无法提供的医疗保健服务。许多健康差异限制了全球对许多头痛药物的获取,尤其是对历来被排除在随机对照试验之外的人群造成了影响,如心脑血管疾病患者和孕妇。此外,尽管针对年轻患者的偏头痛治疗研究取得了进展,但治疗方案仍然有限。获得头痛治疗的途径取决于药物的可获得性、批准情况、经济保障和医疗服务提供者的专业知识等因素。公众认识不足导致政策制定者的忽视以及患者和医疗服务提供者的治疗不力。新型疾病特效药物的推出加剧了全球在获得药物方面的差异,尤其是对被排除在临床试验之外的亚洲、非洲和拉丁美洲国家的影响。虽然北美和欧洲广泛提供偏头痛治疗药物,但全球大多数国家都无法获得这些疗法。医疗保健差距、治疗机会和药物供应是头痛医学中令人担忧的问题。各国医疗体系的差异影响着头痛的治疗,而昂贵的创新药物正在扩大这些差距。医疗从业人员和专家应认识到这些挑战,并努力将治疗障碍降至最低,以在未来实现公平的全球头痛治疗。
{"title":"Health equity, care access and quality in headache – part 2","authors":"Bianca Raffaelli, Eloísa Rubio-Beltrán, Soo-Jin Cho, Roberto De Icco, Alejandro Labastida-Ramirez, Dilara Onan, Raffaele Ornello, Ruth Ruscheweyh, Marta Waliszewska-Prosół, Roberta Messina, Francesca Puledda","doi":"10.1186/s10194-023-01699-7","DOIUrl":"https://doi.org/10.1186/s10194-023-01699-7","url":null,"abstract":"Headache disorders are a global public health concern affecting diverse populations. This review examines headache service organizations in low-, middle-, and high-income countries. It addresses global challenges in pharmacological headache treatment, with a focus on safety, tolerability, reproductive and child health, and outlines disparities in accessing innovative treatments worldwide. Organized headache services are essential due to the wide prevalence and varying severity of headache disorders. The tiered headache service model is globally recognized, although its implementation varies based on financial and workforce considerations. Headache burden affects well-being, causing disability, economic challenges, and work limitations, irrespective of location or income. All nations still require improved diagnosis and treatment, and the majority of countries face obstacles including limited access, awareness, economic barriers, and inadequate health policies. Provided adequate internet availability, telemedicine could help improve health equity by expanding access to headache care, since it can offer patients access to services without lengthy waiting times or extensive travel and can provide healthcare unavailable in underserved areas due to staff shortages. Numerous health disparities restrict global access to many headache medications, especially impacting individuals historically excluded from randomized controlled trials, such as those with cardiovascular and cerebrovascular conditions, as well as pregnant women. Furthermore, despite advancements in researching migraine treatments for young patients, the options for treatment remain limited. Access to headache treatment relies on factors like medication availability, approval, financial coverage, and healthcare provider expertise. Inadequate public awareness leads to neglect by policymakers and undertreatment by patients and healthcare providers. Global access discrepancies are exacerbated by the introduction of novel disease-specific medications, particularly impacting Asian, African, and Latin American nations excluded from clinical trials. While North America and Europe experience broad availability of migraine treatments, the majority of countries worldwide lack access to these therapies. Healthcare disparities, treatment access, and medication availability are concerning issues in headache medicine. Variations in national healthcare systems impact headache management, and costly innovative drugs are widening these gaps. Healthcare practitioners and experts should acknowledge these challenges and work towards minimizing access barriers for equitable global headache care in the future.","PeriodicalId":501630,"journal":{"name":"The Journal of Headache and Pain","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138581533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The burden and trends of headache disorders among the population aged 15–39: a study from 1990 to 2019 15-39 岁人口中头痛疾病的负担和趋势:1990 年至 2019 年的一项研究
Pub Date : 2023-12-13 DOI: 10.1186/s10194-023-01703-0
Ruixia Yuan, Zhuang Tong, Guoliang Xiang, Yingying Xie, Kaixiang Li, Liang Zhang, Xueqing Wang
To analyze the global burden of headache disorders in adolescents and young adults (AYAs). Data of headache disorders in the 15–39 age groups were extracted from GBD 2019. The age-standardized rates (ASRs) of incidence, prevalence, and years lived with disability (YLDs) rate were used to describe the burden. Estimated Annual Percentage Changes (EAPCs) were used to describe the trend from 1990 to 2019. In 2019, the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized YLDs rate (ASYR) in AYAs were 42,473.18 (95% CI: 34,836.35, 50,858.30) per 100,000, 12,566.18 (95% CI: 8542.10, 16,915.68) per 100,000 and 790.32 (95% CI: 129.56, 1786.52) per 100,000, respectively. From 1990 to 2019, the ASRs showed increasing trends, with EAPCs of 0.04 (95% CI: 0.03, 0.06), 0.05 (95% CI: 0.03, 0.07), and 0.08 (95% CI: 0.07, 0.10). Migraine accounted for 91.54% of headache-related YLDs. The burdens in females were higher than those in males, especially for ASYR. This burden was greatest in the high sociodemographic index (SDI) super region. In the temporal trend of ASIR, 127 (62.25%) countries showed upward trends, mainly distributed in East Asia, Central Asia, West Africa, and Western Latin America. The burden of headache disorders in the global population aged 15–39 is severe, especially among females and in countries with high SDI. Furthermore, this burden has been steadily increasing over the past three decades. Those findings assist in implementing targeted intervention measures.
分析全球青少年和青壮年头痛疾病负担。从GBD 2019中提取15-39岁年龄组的头痛疾病数据。发病率、患病率的年龄标准化率(ASRs)和残疾生活年数(YLDs)率被用来描述负担。估计年度百分比变化(EAPCs)用于描述1990年至2019年的趋势。2019年,AYAs的年龄标准化发病率(ASIR)、年龄标准化患病率(ASPR)和年龄标准化YLDs率(ASYR)分别为42,473.18 (95% CI: 34,836.35、50,858.30)/ 100,000、12,566.18 (95% CI: 8542.10、16,915.68)/ 100,000和790.32 (95% CI: 129.56、1786.52)/ 100,000。从1990年到2019年,asr呈上升趋势,EAPCs分别为0.04 (95% CI: 0.03, 0.06)、0.05 (95% CI: 0.03, 0.07)和0.08 (95% CI: 0.07, 0.10)。偏头痛占头痛相关YLDs的91.54%。女性的负担高于男性,尤其是对于ASYR。这种负担在高社会人口指数(SDI)超级地区最大。在时间趋势上,127个(62.25%)国家呈上升趋势,主要分布在东亚、中亚、西非和拉美西部。在全球15-39岁人群中,头痛疾病的负担非常严重,特别是在女性和SDI高的国家中。此外,这一负担在过去三十年中一直在稳步增加。这些发现有助于实施有针对性的干预措施。
{"title":"The burden and trends of headache disorders among the population aged 15–39: a study from 1990 to 2019","authors":"Ruixia Yuan, Zhuang Tong, Guoliang Xiang, Yingying Xie, Kaixiang Li, Liang Zhang, Xueqing Wang","doi":"10.1186/s10194-023-01703-0","DOIUrl":"https://doi.org/10.1186/s10194-023-01703-0","url":null,"abstract":"To analyze the global burden of headache disorders in adolescents and young adults (AYAs). Data of headache disorders in the 15–39 age groups were extracted from GBD 2019. The age-standardized rates (ASRs) of incidence, prevalence, and years lived with disability (YLDs) rate were used to describe the burden. Estimated Annual Percentage Changes (EAPCs) were used to describe the trend from 1990 to 2019. In 2019, the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized YLDs rate (ASYR) in AYAs were 42,473.18 (95% CI: 34,836.35, 50,858.30) per 100,000, 12,566.18 (95% CI: 8542.10, 16,915.68) per 100,000 and 790.32 (95% CI: 129.56, 1786.52) per 100,000, respectively. From 1990 to 2019, the ASRs showed increasing trends, with EAPCs of 0.04 (95% CI: 0.03, 0.06), 0.05 (95% CI: 0.03, 0.07), and 0.08 (95% CI: 0.07, 0.10). Migraine accounted for 91.54% of headache-related YLDs. The burdens in females were higher than those in males, especially for ASYR. This burden was greatest in the high sociodemographic index (SDI) super region. In the temporal trend of ASIR, 127 (62.25%) countries showed upward trends, mainly distributed in East Asia, Central Asia, West Africa, and Western Latin America. The burden of headache disorders in the global population aged 15–39 is severe, especially among females and in countries with high SDI. Furthermore, this burden has been steadily increasing over the past three decades. Those findings assist in implementing targeted intervention measures.","PeriodicalId":501630,"journal":{"name":"The Journal of Headache and Pain","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138631390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of intradialysis blood sodium level, blood pressure variability, and hydration status with hemodialysis-related headache: a prospective cohort study 透析内血钠水平、血压变化和水合状态与血液透析相关头痛的关系:一项前瞻性队列研究
Pub Date : 2023-12-11 DOI: 10.1186/s10194-023-01701-2
Yuqin Xiong, Nujia You, Ruoxi Liao, Ling Wu, Yao Liu, Ziying Ling, Yang Yu
To identify primary factors contributing to hemodialysis-related headache (HRH) in maintenance hemodialysis (MHD) patients. Adult outpatients receiving MHD were prospectively enrolled from a hemodialysis (HD) center of a tertiary hospital in China. Twelve dialysis sessions were successively monitored for each patient. HRH is defined as having at least three headache episodes that begin during HD and resolve within 72 h of HD session completion. Blood gas analysis during headache episodes and body composition analysis after dialysis were conducted. Hour-to-hour vital sign variability during dialysis was assessed using the metric of average real variability (ARV). Multivariable logistic regression analysis was conducted to explore the factors triggering HRH. A total of 95 Chinese MHD patients were enrolled, with 92 patients (60.9% were males) included in the final analysis. The mean age of the 92 patients was 59.3 ± 17.5 years, and the median dialysis vintage was 27.1 (12–46.2) months. Among them, 12 patients (13%) complained of 42 headache attacks, and eight (8.7%) were diagnosed with HRH. For eight patients with HRH, headache occurred 100.3 ± 69.5 min after the start of dialysis, with a mean VAS score of 4.3 ± 1 points. The quality of headaches was dull (six patients), pulsating (one patient), or stabbing pain (one patient); all the headaches were bilateral, with one having concomitant vomiting. The intradialysis headache duration and the whole headache duration were 98.8 ± 68.1 and 120 (65–217.5) minutes, respectively. Younger age (OR = 0.844, 95% CI 0.719–0.991, p = 0.039), decreased blood sodium level (OR = 0.309 in the range of 133–142 mmol/L, 95% CI 0.111–0.856, p = 0.024), increased ARV of intradialysis systolic blood pressure (OR = 3.067, 95% CI 1.006–9.348, p = 0.049) and ratio of overhydration to dry weight (OR = 1.990, 95% CI 1.033–3.832, p = 0.040) were found to be independent risk factors for HRH. This study suggested a significant attribution of blood sodium, hydration status and blood pressure variability to HRH.
旨在确定导致维持性血液透析(MHD)患者血液透析相关性头痛(HRH)的主要因素。研究人员在中国一家三甲医院的血液透析中心对接受血液透析的成人门诊患者进行了前瞻性登记。对每位患者连续进行了 12 次透析监测。HRH的定义是在血液透析过程中至少发作三次头痛,并在透析结束后72小时内缓解。在头痛发作期间进行血气分析,在透析后进行身体成分分析。透析期间每小时的生命体征变异性采用平均实际变异性(ARV)指标进行评估。对引发 HRH 的因素进行了多变量逻辑回归分析。共有 95 名中国血液透析患者入选,其中 92 名患者(60.9% 为男性)被纳入最终分析。92 名患者的平均年龄为 59.3 ± 17.5 岁,中位透析年限为 27.1 (12-46.2) 个月。其中,12 名患者(13%)主诉 42 次头痛发作,8 名患者(8.7%)被诊断为 HRH。8 名 HRH 患者的头痛发生在透析开始后 100.3 ± 69.5 分钟,平均 VAS 评分为 4.3 ± 1 分。头痛的性质为钝痛(6 名患者)、搏动痛(1 名患者)或刺痛(1 名患者);所有头痛均为双侧性,其中 1 名患者伴有呕吐。透析内头痛持续时间和整个头痛持续时间分别为 98.8 ± 68.1 分钟和 120 (65-217.5) 分钟。年龄较小(OR = 0.844,95% CI 0.719-0.991,p = 0.039)、血钠水平降低(OR = 0.309,范围在 133-142 mmol/L,95% CI 0.111-0.856,p = 0.024)、透析内收缩压 ARV 升高(OR = 3.067,95% CI 1.006-9.348,p = 0.049)和过量脱水与干体重之比(OR = 1.990,95% CI 1.033-3.832,p = 0.040)被认为是 HRH 的独立危险因素。该研究表明,血钠、水合状态和血压变异是导致 HRH 的重要因素。
{"title":"Association of intradialysis blood sodium level, blood pressure variability, and hydration status with hemodialysis-related headache: a prospective cohort study","authors":"Yuqin Xiong, Nujia You, Ruoxi Liao, Ling Wu, Yao Liu, Ziying Ling, Yang Yu","doi":"10.1186/s10194-023-01701-2","DOIUrl":"https://doi.org/10.1186/s10194-023-01701-2","url":null,"abstract":"To identify primary factors contributing to hemodialysis-related headache (HRH) in maintenance hemodialysis (MHD) patients. Adult outpatients receiving MHD were prospectively enrolled from a hemodialysis (HD) center of a tertiary hospital in China. Twelve dialysis sessions were successively monitored for each patient. HRH is defined as having at least three headache episodes that begin during HD and resolve within 72 h of HD session completion. Blood gas analysis during headache episodes and body composition analysis after dialysis were conducted. Hour-to-hour vital sign variability during dialysis was assessed using the metric of average real variability (ARV). Multivariable logistic regression analysis was conducted to explore the factors triggering HRH. A total of 95 Chinese MHD patients were enrolled, with 92 patients (60.9% were males) included in the final analysis. The mean age of the 92 patients was 59.3 ± 17.5 years, and the median dialysis vintage was 27.1 (12–46.2) months. Among them, 12 patients (13%) complained of 42 headache attacks, and eight (8.7%) were diagnosed with HRH. For eight patients with HRH, headache occurred 100.3 ± 69.5 min after the start of dialysis, with a mean VAS score of 4.3 ± 1 points. The quality of headaches was dull (six patients), pulsating (one patient), or stabbing pain (one patient); all the headaches were bilateral, with one having concomitant vomiting. The intradialysis headache duration and the whole headache duration were 98.8 ± 68.1 and 120 (65–217.5) minutes, respectively. Younger age (OR = 0.844, 95% CI 0.719–0.991, p = 0.039), decreased blood sodium level (OR = 0.309 in the range of 133–142 mmol/L, 95% CI 0.111–0.856, p = 0.024), increased ARV of intradialysis systolic blood pressure (OR = 3.067, 95% CI 1.006–9.348, p = 0.049) and ratio of overhydration to dry weight (OR = 1.990, 95% CI 1.033–3.832, p = 0.040) were found to be independent risk factors for HRH. This study suggested a significant attribution of blood sodium, hydration status and blood pressure variability to HRH.","PeriodicalId":501630,"journal":{"name":"The Journal of Headache and Pain","volume":"231 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138565849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Compromised trigemino-coerulean coupling in migraine sensitization can be prevented by blocking beta-receptors in the locus coeruleus 阻断小脑位置的β受体可防止偏头痛致敏过程中三叉神经-小脑耦合功能受损
Pub Date : 2023-12-08 DOI: 10.1186/s10194-023-01691-1
Jérémy Signoret-Genest, Maxime Barnet, François Gabrielli, Youssef Aissouni, Alain Artola, Radhouane Dallel, Myriam Antri, Philip Tovote, Lénaïc Monconduit
Migraine is a disabling neurological disorder, characterized by recurrent headaches. During migraine attacks, individuals often experience sensory symptoms such as cutaneous allodynia which indicates the presence of central sensitization. This sensitization is prevented by oral administration of propranolol, a common first-line medication for migraine prophylaxis, that also normalized the activation of the locus coeruleus (LC), considered as the main origin of descending noradrenergic pain controls. We hypothesized that the basal modulation of trigeminal sensory processing by the locus coeruleus is shifted towards more facilitation in migraineurs and that prophylactic action of propranolol may be attributed to a direct action in LC through beta-adrenergic receptors. We used simultaneous in vivo extracellular recordings from the trigeminocervical complex (TCC) and LC of male Sprague–Dawley rats to characterize the relationship between these two areas following repeated meningeal inflammatory soup infusions. Von Frey Hairs and air-puff were used to test periorbital mechanical allodynia. RNAscope and patch-clamp recordings allowed us to examine the action mechanism of propranolol. We found a strong synchronization between TCC and LC spontaneous activities, with a precession of the LC, suggesting the LC drives TCC excitability. Following repeated dural-evoked trigeminal activations, we observed a disruption in coupling of activity within LC and TCC. This suggested an involvement of the two regions’ interactions in the development of sensitization. Furthermore, we showed the co-expression of alpha-2A and beta-2 adrenergic receptors within LC neurons. Finally propranolol microinjections into the LC prevented trigeminal sensitization by desynchronizing and decreasing LC neuronal activity. Altogether these results suggest that trigemino-coerulean coupling plays a pivotal role in migraine progression, and that propranolol’s prophylactic effects involve, to some extent, the modulation of LC activity through beta-2 adrenergic receptors. This insight reveals new mechanistic aspects of LC control over sensory processing.
偏头痛是一种致残性神经系统疾病,以反复发作的头痛为特征。偏头痛发作时,患者通常会出现皮肤异感症等感觉症状,这表明存在中枢过敏现象。口服普萘洛尔(预防偏头痛的常用一线药物)可防止这种过敏现象的发生,同时还能使被认为是降级去甲肾上腺素能疼痛控制主要源头的大脑皮质(LC)的激活恢复正常。我们推测,偏头痛患者三叉神经感觉处理过程中枢的基础调节作用已转向更多的促进作用,而普萘洛尔的预防作用可能是通过β肾上腺素能受体直接作用于LC。我们使用从雄性 Sprague-Dawley 大鼠的三叉神经颈复合体(TCC)和 LC 同时进行的体内细胞外记录来描述这两个区域在反复脑膜炎症汤剂输注后的关系。Von Frey Hairs 和气囊用于测试眶周机械异感。通过 RNAscope 和膜片钳记录,我们研究了普萘洛尔的作用机制。我们发现 TCC 和 LC 自发活动之间有很强的同步性,LC 有前驱性,这表明 LC 驱动着 TCC 的兴奋性。在硬脑膜诱发的三叉神经反复激活后,我们观察到 LC 和 TCC 活动的耦合出现了中断。这表明这两个区域的相互作用参与了敏感性的发展。此外,我们还发现α-2A和β-2肾上腺素能受体在LC神经元内共同表达。最后,将普萘洛尔微量注射到 LC 中,通过去同步化和减少 LC 神经元的活动来防止三叉神经致敏。总之,这些结果表明,三叉神经-丘脑耦合在偏头痛的发展过程中起着关键作用,而普萘洛尔的预防作用在一定程度上涉及通过β-2肾上腺素能受体调节LC的活动。这一观点揭示了LC控制感觉处理的新机理。
{"title":"Compromised trigemino-coerulean coupling in migraine sensitization can be prevented by blocking beta-receptors in the locus coeruleus","authors":"Jérémy Signoret-Genest, Maxime Barnet, François Gabrielli, Youssef Aissouni, Alain Artola, Radhouane Dallel, Myriam Antri, Philip Tovote, Lénaïc Monconduit","doi":"10.1186/s10194-023-01691-1","DOIUrl":"https://doi.org/10.1186/s10194-023-01691-1","url":null,"abstract":"Migraine is a disabling neurological disorder, characterized by recurrent headaches. During migraine attacks, individuals often experience sensory symptoms such as cutaneous allodynia which indicates the presence of central sensitization. This sensitization is prevented by oral administration of propranolol, a common first-line medication for migraine prophylaxis, that also normalized the activation of the locus coeruleus (LC), considered as the main origin of descending noradrenergic pain controls. We hypothesized that the basal modulation of trigeminal sensory processing by the locus coeruleus is shifted towards more facilitation in migraineurs and that prophylactic action of propranolol may be attributed to a direct action in LC through beta-adrenergic receptors. We used simultaneous in vivo extracellular recordings from the trigeminocervical complex (TCC) and LC of male Sprague–Dawley rats to characterize the relationship between these two areas following repeated meningeal inflammatory soup infusions. Von Frey Hairs and air-puff were used to test periorbital mechanical allodynia. RNAscope and patch-clamp recordings allowed us to examine the action mechanism of propranolol. We found a strong synchronization between TCC and LC spontaneous activities, with a precession of the LC, suggesting the LC drives TCC excitability. Following repeated dural-evoked trigeminal activations, we observed a disruption in coupling of activity within LC and TCC. This suggested an involvement of the two regions’ interactions in the development of sensitization. Furthermore, we showed the co-expression of alpha-2A and beta-2 adrenergic receptors within LC neurons. Finally propranolol microinjections into the LC prevented trigeminal sensitization by desynchronizing and decreasing LC neuronal activity. Altogether these results suggest that trigemino-coerulean coupling plays a pivotal role in migraine progression, and that propranolol’s prophylactic effects involve, to some extent, the modulation of LC activity through beta-2 adrenergic receptors. This insight reveals new mechanistic aspects of LC control over sensory processing.","PeriodicalId":501630,"journal":{"name":"The Journal of Headache and Pain","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138557159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
The Journal of Headache and Pain
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1